Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
32 hedge funds and large institutions have $7.35M invested in Impel Pharmaceuticals Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 32 → 32 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
67% less capital invested
Capital invested by funds: $22.3M → $7.35M (-$14.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$20.6K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$20.4K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$19.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.6K |
| 5 |
VF
Virtu Financial
New York
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Lasry Marc
|
-$175K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$158K |
| 3 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$120K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$80.4K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$63K |
IMPL Hedge Fund Activity: Q3 2023 in Review
32 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q3 2023, worth a combined $7.35M — down 67% from $22.3M a quarter earlier.
Fund positioning in IMPL was balanced in Q3 2023: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $20.6K. The largest seller was Lasry Marc, cutting an estimated $175K.
- 32 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $7.35M of Impel Pharmaceuticals Inc. Common Stock stock for Q3 2023, down 67% quarter-over-quarter.
- 5 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q3 2023 and 5 closed out, a net change of 0 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q3 2023 was Millennium Management, an estimated $20.6K added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q3 2023 was Lasry Marc, an estimated $175K sold.
Based on aggregated 13F filings for Q3 2023.